Romosozumab versus Alendronate and Fracture Risk in Women with Osteoporosis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Song, Gwan G. | - |
dc.contributor.author | Lee, Young H. | - |
dc.date.accessioned | 2021-09-02T16:11:50Z | - |
dc.date.available | 2021-09-02T16:11:50Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2018-01-11 | - |
dc.identifier.issn | 0028-4793 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/77987 | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | MASSACHUSETTS MEDICAL SOC | - |
dc.title | Romosozumab versus Alendronate and Fracture Risk in Women with Osteoporosis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Song, Gwan G. | - |
dc.contributor.affiliatedAuthor | Lee, Young H. | - |
dc.identifier.doi | 10.1056/NEJMc1714810 | - |
dc.identifier.scopusid | 2-s2.0-85041106809 | - |
dc.identifier.wosid | 000419971600015 | - |
dc.identifier.bibliographicCitation | NEW ENGLAND JOURNAL OF MEDICINE, v.378, no.2, pp.194 - 194 | - |
dc.relation.isPartOf | NEW ENGLAND JOURNAL OF MEDICINE | - |
dc.citation.title | NEW ENGLAND JOURNAL OF MEDICINE | - |
dc.citation.volume | 378 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 194 | - |
dc.citation.endPage | 194 | - |
dc.type.rims | ART | - |
dc.type.docType | Letter | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.